Skip to main content
. 2023 Aug 10;17:1586. doi: 10.3332/ecancer.2023.1586

Table 2. Pathological response.

Cohort 1: Capecitabine Cohort 2: 5-FU
PPI (51) Non-PPI (200) p value PPI (52) Non-PPI (144) p value
ypCR 29.4% 19.5% 0.13 25.0% 26.4% 1.00
ypPR 47.1% 52.5% 61.5% 50.0%
ypCR + ypPR 76.5% 72.0% 0.60 86.5% 76.4% 0.16
ypSD 17.6% 18.5% 7.7% 13.2%
ypPD 8.8% 9.5% 5.8% 10.4%

PPI: proton-pump inhibitors; ypCR: pathological complete response; ypPR: pathological partial response; ypSD: pathological stable disease; ypPD: pathological progressive disease